Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives $10.14 Average PT from Analysts

Aquestive Therapeutics, Inc. (NASDAQ:AQST - Get Free Report) has been assigned a consensus rating of "Buy" from the seven analysts that are presently covering the stock, MarketBeat Ratings reports. Seven equities research analysts have rated the stock with a buy recommendation. The average 1-year price target among brokers that have covered the stock in the last year is $10.14.

Several brokerages have recently issued reports on AQST. HC Wainwright reiterated a "buy" rating and set a $10.00 price target on shares of Aquestive Therapeutics in a report on Tuesday, June 17th. Oppenheimer started coverage on Aquestive Therapeutics in a report on Monday, June 2nd. They set an "outperform" rating and a $7.00 price target for the company.

Institutional Investors Weigh In On Aquestive Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Summit Wealth & Retirement Planning Inc. acquired a new stake in Aquestive Therapeutics in the 1st quarter worth approximately $29,000. Victory Capital Management Inc. bought a new stake in shares of Aquestive Therapeutics in the first quarter valued at approximately $31,000. Cambridge Investment Research Advisors Inc. bought a new stake in shares of Aquestive Therapeutics in the first quarter valued at approximately $33,000. Dynamic Technology Lab Private Ltd bought a new stake in shares of Aquestive Therapeutics in the fourth quarter valued at approximately $44,000. Finally, Two Sigma Advisers LP bought a new stake in shares of Aquestive Therapeutics in the fourth quarter valued at approximately $57,000. 32.45% of the stock is currently owned by institutional investors and hedge funds.

Aquestive Therapeutics Trading Down 0.5%

NASDAQ:AQST traded down $0.02 on Wednesday, hitting $4.01. 1,146,536 shares of the company's stock traded hands, compared to its average volume of 1,495,973. Aquestive Therapeutics has a 1 year low of $2.12 and a 1 year high of $5.80. The firm has a 50-day moving average price of $3.10 and a 200-day moving average price of $3.01.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last announced its quarterly earnings results on Monday, May 12th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.07). The firm had revenue of $8.72 million during the quarter, compared to analyst estimates of $12.23 million. As a group, equities research analysts forecast that Aquestive Therapeutics will post -0.46 earnings per share for the current fiscal year.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.